Aga Khan University at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Aga Khan University brings 4 presentations to ESGCT 2026 in Hamburg. Its work covers beta-thalassemia and other haemoglobin disorders, including prime editing in patient-derived stem cells and silencing of ZNF410 and BCL11A to raise fetal haemoglobin. A separate strand develops an accessible CD19 CAR T platform for patients in Pakistan.
| Organization | ESGCT 2026 Attendance |
|---|---|
Aga Khan University Karachi, Pakistan | |
Poster Wed Oct 28 1:30pm–3:30pm Comparative evaluation of non-viral nanocarriers for siRNA and mRNA delivery in different hematopoietic cell models Poster Wed Oct 28 1:30pm–3:30pm Developing an efficacious and highly accessible CD19 CAR T-cell therapeutic platform for B-cellmalignancies in Pakistani patients Poster Wed Oct 28 1:30pm–3:30pm Silencing ZNF410/BCL11A as therapeutic targets for fetal hemoglobin induction in β-hemoglobinopathies Rare and inherited disease Poster Thu Oct 29 2:00pm–4:00pm Prime Editing Restores Functional Adult β-Globin Expression in Patient-Derived β-Thalassemia iPSCs |
Instantly find 20 buyers from Aga Khan University
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction